...suspension, arikace, slit amikacin) Ayvakit, avapritinib (blu-285) belantamab mafodotin, J6M0-mcMMAF (2857916, GSK2857916) Calquence (Brand), ACP-196 (Compound #), acalabrutinib (Generic) bupivacaine/meloxicam...

...endpoints in the Phase III INTERCEPT trial for early treatment of migraine. Administration of the meloxicam/rizatriptan...

...CMC and non-clinical information for the long-acting formulation of bupivacaine in a fixed-dose combination with meloxicam...

...Pink:ZCOR) with a new focus on non-opioid analgesics through the acquisition of four programs from Iroko...

...unit of Boehringer Ingelheim GmbH secured market share for the non-steroidal anti-inflammatory drug (NSAID) Mobic meloxicam...

...a niche for AXS-07 in acute migraine. Axsome Therapeutics Inc. (NASDAQ:AXSM) said Monday that its meloxicam/rizatriptan...
...administered, fixed-dose AXS-07 combines the company’s Molecular Solubility Enhanced Inclusion Complex (MoSEIC) meloxicam and rizatriptan. Meloxicam...
...said on the call. “Axsome’s MoSEIC technology significantly increases the speed of absorption of the meloxicam...

...CMC and non-clinical information for the long-acting formulation of bupivacaine in a fixed-dose combination with meloxicam...

...CMC and non-clinical information for the long-acting formulation of bupivacaine in a fixed-dose combination with meloxicam...

...Assessment. AXS-07 is an oral, fixed dose combination of Molecular Solubility Enhanced Inclusion Complex (MoSEIC) meloxicam...
...burden (TMB) Recro Pharma Inc. (NASDAQ:REPH) FDA issues a second complete response letter for IV meloxicam...

...Recro said FDA issued a second complete response letter for its NDA for IV meloxicam (N1539...
...Recro Pharma Inc. (NASDAQ:REPH) said the agency was concerned with onset and duration of IV meloxicam...
...drugs. The company also said the letter cited regulatory concerns about the role of IV meloxicam...